Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of “Buy” by Analysts

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) have received an average rating of “Buy” from the seventeen ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $77.20.

Several brokerages recently weighed in on XENE. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. JPMorgan Chase & Co. upped their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Needham & Company LLC cut their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Finally, Royal Bank Of Canada lifted their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, May 8th.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director directly owned 1,455 shares in the company, valued at $77,318.70. The trade was a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the sale, the director owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.91% of the company’s stock.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Avoro Capital Advisors LLC lifted its holdings in shares of Xenon Pharmaceuticals by 0.5% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock valued at $243,124,000 after acquiring an additional 24,444 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Xenon Pharmaceuticals by 2.3% in the 1st quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company’s stock valued at $242,858,000 after purchasing an additional 91,948 shares in the last quarter. Wellington Management Group LLP increased its holdings in Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after purchasing an additional 1,435,096 shares in the last quarter. Capital International Investors raised its position in Xenon Pharmaceuticals by 7.3% in the fourth quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after purchasing an additional 233,466 shares during the period. Finally, Commodore Capital LP raised its position in Xenon Pharmaceuticals by 30.1% in the second quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after purchasing an additional 700,000 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $68.26 on Monday. The company has a market cap of $6.60 billion, a P/E ratio of -14.52 and a beta of 0.61. The firm’s 50 day moving average is $57.24 and its two-hundred day moving average is $51.92. Xenon Pharmaceuticals has a fifty-two week low of $30.00 and a fifty-two week high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.17). During the same quarter in the previous year, the firm earned ($0.83) EPS. Research analysts forecast that Xenon Pharmaceuticals will post -4.92 earnings per share for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.